(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -8.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Biontech Se's revenue in 2026 is $3,376,352,941.On average, 26 Wall Street analysts forecast BNTX's revenue for 2026 to be $550,013,082,768, with the lowest BNTX revenue forecast at $471,302,659,056, and the highest BNTX revenue forecast at $725,671,711,296. On average, 25 Wall Street analysts forecast BNTX's revenue for 2027 to be $576,169,900,404, with the lowest BNTX revenue forecast at $339,318,716,856, and the highest BNTX revenue forecast at $826,459,448,976.
In 2028, BNTX is forecast to generate $628,243,564,872 in revenue, with the lowest revenue forecast at $323,240,672,988 and the highest revenue forecast at $950,284,383,840.